An update on pharmacotherapy for the treatment of fibromyalgia

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 9, 2015, Pages 1347-1368

  Calandre, Elena P ^a   Rico Villademoros, Fernando ^a   Slim, Mahmoud ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

Drug efficacy; Drug tolerability; Drug treatment; Fibromyalgia; Review

Indexed keywords

AMITRIPTYLINE; CANNABINOID; CYCLOBENZAPRINE; DULOXETINE; GABAPENTIN; MILNACIPRAN; MOCLOBEMIDE; NABILONE; OXYBATE SODIUM; PIRLINDOLE; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TROPISETRON; ADRENERGIC RECEPTOR AFFECTING AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; MONOAMINE OXIDASE INHIBITOR; NEW DRUG;

CLINICAL EFFECTIVENESS; DEPRESSION; DRUG APPROVAL; DRUG TOLERABILITY; EUROPEAN MEDICINES AGENCY; FATIGUE; FIBROMYALGIA; FIBROMYALGIA IMPACT QUESTIONNAIRE; FOOD AND DRUG ADMINISTRATION; HUMAN; LONG TERM CARE; PAIN; PATIENT DROPOUTS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SLEEP DISORDER; SLEEP QUALITY; PATHOPHYSIOLOGY;

ADRENERGIC UPTAKE INHIBITORS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; DRUGS, INVESTIGATIONAL; FIBROMYALGIA; HUMANS; MONOAMINE OXIDASE INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS;

EID: 84929920450     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1047343     Document Type: Review

References (125)

1. Smith HS, Barkin RL. Fibromyalgia syndrome: a discussion of the syndrome and pharmacotherapy. Dis Mon 2011;57:248-85
2. Clauw DJ, Arnold LM, McCarberg BH. The science of fibromyalgia. Mayo Clin Proc 2011;86:907-11
3. Queiroz LP. Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep 2013;17:356
4. Weir PT, Harlan GA, Nkoy FL, et al. The incidence of fibromyalgia and its associated comorbidities: a populationbased retrospective cohort study based on International Classification of Diseases, 9th Revision codes. J Clin Rheumatol 2006;12:124-8
5. Aaron LA, Buchwald D. Chronic diffuse musculoskeletal pain, fibromyalgia and co-morbid unexplained clinical conditions. Best Pract Res Clin Rheumatol 2003;17:563-74
6. White LA, Birnbaum HG, Kaltenboeck A, et al. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med 2008;50:13-24
7. Skaer TL. Fibromyalgia: disease synopsis, medication cost effectiveness and economic burden. Pharmacoeconomics 2014;32:457-66
8. Sarzi-Puttini P, Atzeni F, Salaffi F, et al. Multidisciplinary approach to fibromyalgia: what is the teaching? Best Pract Res Clin Rheumatol 2011;25:311-19
9. Hauser W, Thieme K, Turk DC. Guidelines on the management of fibromyalgia syndrome-A systematic review. Eur J Pain 2010;14:5-10
10. Ablin J, Fitzcharles MA, Buskila D, et al. Treatment of fibromyalgia syndrome: recommendations of recent evidencebased interdisciplinary guidelines with special emphasis on complementary and alternative therapies. Evid Based Complement Alternat Med 2013;2013:485272
11. Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008;67:536-41
12. Hauser W, Arnold B, Eich W, et al. Management of fibromyalgia syndrome-An interdisciplinary evidence-based guideline. Ger Med Sci 2008;6:Doc14
13. de Miquel CA, Campayo J, Florez MT, et al. Interdisciplinary consensus document for the treatment of fibromyalgia. Actas Esp Psiquiatr 2010;38:108-20
14. Fitzcharles MA, Ste-Marie PA, Goldenberg DL, et al. 2012;Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Res Manag 2013;18:119-26
15. Mika J, Zychowska M, Makuch W, et al. Neuronal and immunological basis of action of antidepressants in chronic pain-clinical and experimental studies. Pharmacol Rep 2013;65:1611-21
16. Heymann RE, Helfenstein M, Feldman D. A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures. Clin Exp Rheumatol 2001;19:697-702
17. Caruso I, Sarzi Puttini PC, Boccassini L, et al. Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 1987;15:154-9
18. Carette S, McCain GA, Bell DA, et al. Evaluation of amitriptyline in primary fibrositis. A double-blind, placebocontrolled study. Arthritis Rheum 1986;29:655-9
19. Carette S, Bell MJ, Reynolds WJ, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum 1994;37:32-40
20. Carette S, Oakson G, Guimont C, et al. Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. Arthritis Rheum 1995;38:1211-17
21. Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 1986;29:1371-7
22. Goldenberg D, Mayskiy M, Mossey C, et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996;39:1852-9
23. Scudds RA, McCain GA, Rollman GB, et al. Improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline. J Rheumatol Suppl 1989;19:98-103
24. Isomeri R, Mikkelsson M, Latikka P, et al. Effects of amitriptyline and cardiovascular fitness training on pain in patients with primary fibromyalgia. J Musculoskelet Pain 1993;1:253-60
25. Kempenaers C, Simenon G, VanDer Elst M, et al. Effect of an antidiencephalon immune serum on pain and sleep in primary fibromyalgia. Neuropsychobiology 1994;30:66-72
26. Ginsberg F, Mancaux A, Joos E, et al. A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia. J Musculoskelet Pain 1996;4:37-47
27. Ataoglu S, Ataoglu A, Erdogan F, et al. Comparison of paroxetine, amitriptyline in the treatment of fibromyalgia. Turk J Med Sci 1997;27:535-9
28. Hannonen P, Malminiemi K, Yli-Kerttula U, et al. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorDer. Br J Rheumatol 1998;37:1279-86
29. Capaci K, Hepguler S. Comparison of the effects of amitriptyline and paroxetine in the treatment of fibromyalgia syndrome. Pain Clinic 2002;14:223-8
30. Gur A, Karakoc M, Nas K, et al. Effects of low power laser and low dose amitriptyline therapy on clinical symptoms and quality of life in fibromyalgia: a single-blind, placebocontrolled trial. Rheumatol Int 2002;22:188-93
31. Konuk N, Ortancil O, Bostanci B, et al. A comparison of reboxetine and amitryptilline in the treatment of fibromyalgia syndrome with co-morbid depressive symptoms: An open-label preliminary study. Klin Psikofarmakol Bul 2010;20:29-37
32. Vlainich R, Issy AM, Sakata RK. Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clin J Pain 2011;27:285-8
33. Calandre EP, Rico-Villademoros F, Galan J, et al. Quetiapine extendedrelease (Seroquel-XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16-week, randomized, flexible-dose, open-label trial. Psychopharmacology (Berl) 2014;231:2525-31
34. Erhan E, Uyar M, Turan S, et al. Fluvoxamine versus amitriptyline in the treatment of fibromyalgia. Agri 2000;12:32-6
35. Hauser W, Petzke F, Uceyler N, et al. Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-Analysis. Rheumatology (Oxford) 2011;50:532-43
36. Smith B, Peterson K, Fu R, et al. Drug Class Review: Drugs for Fibromyalgia: Final Original Report [Internet]. 2011/06/21 edition. Oregon Health &Science University; Portland (OR): 2011
37. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorDer. Arthritis Rheum 2004;50:2974-84
38. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebocontrolled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorDer. Pain 2005;119:5-15
39. Arnold LM, Clauw D, Wang F, et al. Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. J Rheumatol 2010;37:2578-86
40. Arnold LM, Wang F, Ahl J, et al. Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebocontrolled trial. Arthritis Res Ther 2011;13:R86
41. Arnold LM, Zhang S, Pangallo BA. Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebocontrolled study. Clin J Pain 2012;28:775-81
42. Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorDer: Results from a 6-month, randomized, double-blind, placebocontrolled, fixed-dose trial. Pain 2008;136:432-44
43. Chappell AS, Bradley LA, Wiltse C, et al. A six-month double-blind, placebocontrolled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med 2008;1:91-102
44. Chappell AS, Littlejohn G, Kajdasz DK, et al. A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia. Clin J Pain 2009;25:365-75
45. Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005;32:1975-85
46. Clauw DJ, Mease P, Palmer RH, et al. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008;30:1988-2004
47. Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, doubleblind, placebo-controlled trial. J Rheumatol 2009;36:398-409
48. Arnold LM, Gendreau RM, Palmer RH, et al. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:2745-56
49. Arnold LM, Palmer RH, Ma Y. A. 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia. Clin J Pain 2013;29:1021-8
50. Goldenberg DL, Clauw DJ, Palmer RH, et al. Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study. Pain Med 2010;11:180-94
51. Branco JC, Zachrisson O, Perrot S, et al. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. J Rheumatol 2010;37:851-9
52. Branco JC, Cherin P, Montagne A, et al. Longterm therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study. J Rheumatol 2011;38:1403-12
53. Matthey A, Cedraschi C, Piguet V, et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician 2013;16:E553-62
54. Bateman L, Palmer RH, Trugman JM, et al. Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. J Pain Res 2013;6:311-18
55. Hauser W, Urrutia G, Tort S, et al. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. The Cochrane database of systematic reviews 2013;1:CD010292
56. Norregaard J, Volkmann H, Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995;61:445-9
57. AnDerberg UM, Marteinsdottir I, Von Knorring L. Citalopram in patients with fibromyalgia-A randomized, doubleblind, placebo-controlled study. Eur J Pain 2000;4:27-35
58. Kayiran S, Dursun E, Dursun N, et al. Neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial. Appl Psychophysiol Biofeedback 2010;35:293-302
59. Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 1994;23:255-9
60. Cantini F, Bellandi F, Niccoli L, et al. [Fluoxetin combined with cyclobenzaprine in the treatment of fibromyalgia]. Minerva Med 1994;85:97-100
61. Cantini F, Niccoli L, Bellandi F, et al. Effectiveness of fluoxetine associated with cyclobenzaprine in the treatment of fibromyalgia: Twelve-months-follow up results. Reumatismo 1995;47:103-8
62. Arnold LM, Hess EV, Hudson JI, et al. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002;112:191-7
63. Hadianfard MJ, Hosseinzadeh Parizi M. A randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine. Iran Red Crescent Med J 2012;14:631-40
64. Giordano N, Geraci S, Santacroce C, et al. Efficacy and tolerability of paroxetine in patients with fibromyalgia syndrome: A single-blind study. Curr Ther Res Clin Exp 1999;60:696-702
65. Sencan S, Ak S, Karan A, et al. A study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome. J Back Musculoskelet Rehabil 2004;17:57-61
66. Patkar AA, Masand PS, Krulewicz S, et al. A Randomized, Controlled, Trial of Controlled Release Paroxetine in Fibromyalgia. Am J Med 2007;120:448-54
67. Gonzalez-Viejo MA, Avellanet M, Hernandez-Morcuende MI. A comparative study of fibromyalgia treatment: Ultrasonography and physiotherapy versus sertraline treatment. Ann Readapt Med Phys 2005;48:610-15
68. Hauser W, Wolfe F, Tolle T, et al. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-Analysis. CNS Drugs 2012;26:297-307
69. Yavuzer G, Kucukdeveci A, Arasil T, et al. Moclobemid treatment in primary fibromyalgia syndrome. Eur J Phys Med Rehabil 1998;8:35-8
70. Ginsberg F, Joos E, Geczy J, et al. A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia. J Musculoskelet Pain 1998;6:5-17
71. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebocontrolled trial. Arthritis Rheum 2005;52:1264-73
72. Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 2008;136:419-31
73. Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebocontrolled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008;35:502-14
74. Mease PJ, Farmer MV, Palmer RH, et al. Milnacipran combined with pregabalin in fibromyalgia: a randomized, open-label study evaluating the safety and efficacy of adding milnacipran in patients with incomplete response to pregabalin. Ther Adv Musculoskelet Dis 2013;5:113-26
75. Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007;56:1336-44
76. Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008;9:792-805
77. Pauer L, Winkelmann A, Arsenault P, et al. An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumatol 2011;38:2643-52
78. Roth T, Lankford DA, Bhadra P, et al. Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebocontrolled, 2-way crossover polysomnography study. Arthritis Care Res (Hoboken) 2012;64:597-606
79. Ohta H, Oka H, Usui C, et al. A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia. Arthritis Res Ther 2012;14:R217
80. Ohta H, Oka H, Usui C, et al. An open-label long-term phase III extension trial to evaluate the safety and efficacy of pregabalin in Japanese patients with fibromyalgia. Mod Rheumatol 2013;23:1108-15
81. Nasser K, Kivitz AJ, Maricic MJ, et al. Twice daily versus once nightly dosing of pregabalin for fibromyalgia: a doubleblind randomized clinical trial of efficacy and safety. Arthritis Care Res (Hoboken) 2014;66:293-300
82. Hauser W, Bernardy K, Uceyler N, et al. Treatment of fibromyalgia syndrome with gabapentin and pregabalin-A metaanalysis of randomized controlled trials. Pain 2009;145:69-81
83. Bennett RM, Gatter RA, Campbell SM, et al. A comparison of cyclobenzaprine and placebo in the management of fibrositis. A double-blind controlled study. Arthritis Rheum 1988;31:1535-42
84. Quimby LG, Gratwick GM, Whitney CD, et al. A randomized trial of cyclobenzaprine for the treatment of fibromyalgia. J Rheumatol Suppl 1989;19:140-3
85. Reynolds WJ, Moldofsky H, Saskin P, et al. The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia. J Rheumatol 1991;18:452-4
86. Fossaluzza V, De Vita S. Combined therapy with cyclobenzaprine and ibuprofen in primary fibromyalgia syndrome. Int J Clin Pharmacol Res 1992;12:99-102
87. Santandrea S, Montrone F, Sarzi-Puttini P, et al. A double-blind crossover study of two cyclobenzaprine regimens in primary fibromyalgia syndrome. J Int Med Res 1993;21:74-80
88. Garcia J, Simon MA, Duran M, et al. Differential efficacy of a cognitivebehavioral intervention versus pharmacological treatment in the management of fibromyalgic syndrome. Psychol Health Med 2006;11:498-506
89. Moldofsky H, Harris HW, Archambault WT, et al. Effects of bedtime very low dose cyclobenzaprine on symptoms and sleep physiology in patients with fibromyalgia syndrome: a double-blind randomized placebocontrolled study. J Rheumatol 2011;38:2653-63
90. Tofferi JK, Jackson JL, OMalley PG. Treatment of fibromyalgia with cyclobenzaprine: A meta-Analysis. Arthritis Rheum 2004;51:9-13
91. Biasi G, Manca S, Manganelli S, et al. Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo. Int J Clin Pharmacol Res 1998;18:13-19
92. Russell IJ, Kamin M, Bennett RM, et al. Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol 2000;6:250-7
93. Bennett RM, Kamin M, Karim R, et al. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 2003;114:537-45
94. Farber L, Stratz T, Bruckle W, et al. Efficacy and tolerability of tropisetron in primary fibromyalgia-A highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study Group. Scand J Rheumatol Suppl 2000;113:49-54
95. Spath M, Stratz T, Neeck G, et al. Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia. Scand J Rheumatol 2004;33:267-70
96. Seidel MF, Weinreich GF, Stratz T, et al. 5-HT3 receptor antagonists regulate autonomic cardiac dysfunction in primary fibromyalgia syndrome. Rheumatol Int 2007;27:1025-30
97. Vergne-Salle P, Dufauret-Lombard C, Bonnet C, et al. A randomised, doubleblind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia. Eur J Pain 2011;15:509-14
98. Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 2005;52:2495-505
99. Wood PB, Holman AJ. An elephant among us: the role of dopamine in the pathophysiology of fibromyalgia. J Rheumatol 2009;36:221-4
100. Staud R. Sodium oxybate for the treatment of fibromyalgia. Expert Opin Pharmacother 2011;12:1789-98
101. Scharf MB, Baumann M, Berkowitz DV. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol 2003;30:1070-4
102. Russell IJ, Perkins AT, Michalek JE. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum 2009;60:299-309
103. Russell IJ, Holman AJ, Swick TJ, et al. Sodium oxybate reduces pain, fatigue, and sleep disturbance and improves functionality in fibromyalgia: results from a 14-week, randomized, double-blind, placebo-controlled study. Pain 2011;152:1007-17
104. Spaeth M, Bennett RM, Benson BA, et al. Sodium oxybate therapy provides multidimensional improvement in fibromyalgia: results of an international phase 3 trial. Ann Rheum Dis 2012;71:935-42
105. Spaeth M, Alegre C, Perrot S, et al. Long-term tolerability and maintenance of therapeutic response to sodium oxybate in an open-label extension study in patients with fibromyalgia. Arthritis Res Ther 2013;15:R185
106. Skrabek RQ, Galimova L, Ethans K, et al. Nabilone for the treatment of pain in fibromyalgia. J Pain 2008;9:164-73
107. Ware MA, Fitzcharles MA, Joseph L, et al. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 2010;110:604-10
108. Arnold LM, Chatamra K, Hirsch I, et al. Safety and efficacy of esreboxetine in patients with fibromyalgia: An 8-week, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2010;32:1618-32
109. Arnold LM, Hirsch I, SanDers P, et al. Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteenweek, randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum 2012;64:2387-97
110. Yeephu S, Suthisisang C, Suttiruksa S, et al. Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. Ann Pharmacother 2013;47:921-32
111. Hussain SA, Al K II, Jasim NA, et al. AdjuVant use of melatonin for treatment of fibromyalgia. J Pineal Res 2011;50:267-71
112. de Zanette SA, Vercelino R, Laste G, et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacol Toxicol 2014;15:40
113. Rico-Villademoros F, Calandre EP, Slim M. Current Status of Atypical Antipsychotics for the Treatment of Fibromyalgia. Drug Today 2014;50:435-44
114. OliVan-Blazquez B, Herrera-Mercadal P, Puebla-Guedea M, et al. Efficacy of memantine in the treatment of fibromyalgia: A double-blind, randomised, controlled trial with 6-month follow-up. Pain 2014;155:2517-25
115. Boyle J, Eriksson ME, Gribble L, et al. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care 2012;35:2451-8
116. Clauw DJ. Fibromyalgia: a clinical review. JAMA 2014;311:1547-55
117. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996;23:1407-17
118. Moldofsky H, Inhaber NH, Guinta DR, et al. Effects of sodium oxybate on sleep physiology and sleep/wake-related symptoms in patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled study. J Rheumatol 2010;37:2156-66
119. Holshoe JM. Antidepressants and sleep: a review. Perspect Psychiatr Care 2009;45:191-7
120. Stahl SM. The psychopharmacology of energy and fatigue. J Clin Psychiatry 2002;63:7-8
121. Mease PJ, Palmer RH, Wang Y. Effects of milnacipran on the multidimensional aspects of fatigue and the relationship of fatigue to pain and function: pooled analysis of 3 fibromyalgia trials. J Clin Rheumatol 2014;20:195-202
122. Wolfe F, AnDerson J, Harkness D, et al. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum 1997;40:1560-70
123. White KP, Nielson WR, Harth M, et al. Does the label fibromyalgia alter health status, function, and health service utilization? A prospective, within-group comparison in a community cohort of adults with chronic widespread pain. Arthritis Rheum 2002;47:260-5
124. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72
125. Calandre EP, Rico-Villademoros F, Rodriguez-Lopez CM. Monotherapy or combination therapy for fibromyalgia treatment? Curr Rheumatol Rep 2012;14:568-75